Comparing the i31-SLNB and the MIA Nomogram for Sentinel Lymph Node Biopsy Positivity Prediction in Cutaneous Melanoma: A Prospective Cohort Analysis - Scorecard - MDSpire
Advertisement
Comparing the i31-SLNB and the MIA Nomogram for Sentinel Lymph Node Biopsy Positivity Prediction in Cutaneous Melanoma: A Prospective Cohort Analysis
Clinical Scorecard: Evaluating the i31-SLNB and MIA Nomogram for Predicting Sentinel Lymph Node Biopsy Positivity in Cutaneous Melanoma: A Prospective Cohort Study
At a Glance
Category
Detail
Condition
Cutaneous Melanoma
Key Mechanisms
i31-SLNB combines 31-GEP score with clinicopathologic factors to predict SLN positivity.
Target Population
Patients with cutaneous melanoma being considered for sentinel lymph node biopsy.
Care Setting
Prospective, multicenter clinical study.
Key Highlights
Patients who avoid SLNB based on i31-SLNB results have no recurrences at a median of 2 years.
Guideline-Based Recommendations
Diagnosis
SLNB is a primary component of the AJCC staging system for cutaneous melanoma.
Management
Avoid SLNB if risk of positive SLN is < 5%; discuss if risk is 5-10%; offer if risk is > 10%.
Monitoring & Follow-up
Patients who avoid SLNB based on i31-SLNB should have low recurrence rates.
Risks
Surgery-associated morbidities include infection, seroma, hematoma, and lymphedema.
Patient & Prescribing Data
Patients with cutaneous melanoma undergoing SLNB.
i31-SLNB aids in decision-making to avoid unnecessary SLNB procedures.
Clinical Best Practices
Utilize i31-SLNB for personalized risk assessment in SLNB decision-making.
